Beth Israel Deaconess Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Beth Israel Deaconess Medical Center sits in the top decile of US sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count).
Beth Israel Deaconess Medical Center: 488 sponsored US clinical trials, 66 recruiting.
Beth Israel Deaconess Medical Center sponsors 488 registered US clinical trials on ClinicalTrials.gov, 66 of them currently recruiting, and 321 completed. 45 of these trials are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 8 trials.
Top-decile sponsor footprint
Beth Israel Deaconess Medical Center ranks in the top decile of sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
321 of 380 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
488 total, page 10 of 10
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00073957
Yoga for Patients With Epilepsy
NCT00179452
Endoscopic Implantation of Enteryx for the Treatment of GERD
NCT00346905
Diagnostic Challenges in IC (and Male CPPS)
NCT00672087
Tea's Effect on Atherosclerosis Pilot Study (TEA Study)
NCT00120107
Effects of Soy Isoflavones on Menopausal Hot Flashes
NCT00179556
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma
NCT00625755
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
NCT00533923
Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00052416
Role of Leptin in the Neuroendocrine and Immune Response to Fasting
NCT00140231
In Vivo Leptin Signaling in Humans After Acute Leptin Administration
NCT01275053
Does the Relaxation Response Inhibit Acute Stress?
NCT00179595
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00055614
Boron Neutron Capture Therapy in Treating Patients With Melanoma
NCT00059800
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
NCT00039572
Self Hypnotic Relaxation As An Adjunct To Local Anesthesia During Large Core Breast Biopsy
NCT00122369
Tracheobronchomalacia: Treatment Outcomes
NCT00550602
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
NCT00140244
Soy Nuts and Cardiovascular Risk in Postmenopausal Women
NCT01740076
Mechanisms and Therapeutic Effects of the Relaxation Response in Elderly Hypertensive Patients
NCT00179543
Cognitive Enhancement Therapy for Early-Stage Schizophrenia
NCT00167362
Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
NCT00179517
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
NCT00179478
Pharmacokinetics of Leptin Administration During Fasting
NCT00140205
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
NCT01250717
Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors
NCT00997529
Progesterone vs Placebo Therapy for Women With Epilepsy
NCT00029536
The Labor and Delivery Teamwork Intervention Trial
NCT00381056
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
NCT00626860
Study of Long-term Peg Intron vs. Colchicine in Non-responders.
NCT00179413
Effect of Antiseizure Medication on Hormone Levels and Sexual Function in Men With Epilepsy
NCT00179426
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
NCT00004082
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
NCT00004081
Tracheal Mechanics During Bronchoscopy
NCT00536315
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
NCT00003741
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance
NCT00004419
Mind-Body Exercise for COPD: A Pilot Study
NCT01007903
Early Functional Outcomes After Closed Reduction With Pinning Versus Open Reduction Internal Fixation of Wrist Fractures
NCT00828685
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 91 |
| Phase 3 | 13 |
| Phase 4 | 32 |
Therapeutic Areas
What is open in the Beth Israel Deaconess Medical Center pipeline
66 recruiting of 488 indexed (14% open); 321 completed (66%).
Phase mix: 45 late (III/IV) vs 144 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Beth Israel Deaconess Medical Center: open-pipeline peers nationwide
Peers matched on 488 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 488 trials (± recruiting share)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Case Comprehensive Cancer Center · 14% recruiting · 407 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Beth Israel Deaconess Medical Center page
488 registered trials is a research-attention snapshot, not an endorsement of Beth Israel Deaconess Medical Center or any single study.
- 66 of Beth Israel Deaconess Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Beth Israel Deaconess Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Beth Israel Deaconess Medical Center pipeline card: 488 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.